Changeflow GovPing Pharma & Drug Safety Neurotrophin Binding Protein p75NTR for Osteoar...
Routine Notice Added Final

Neurotrophin Binding Protein p75NTR for Osteoarthritis Treatment - Patent EP3169347A1

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3169347A1 on April 8, 2026, covering neurotrophin binding protein p75NTR for use in treating osteoarthritis. Applicant Levicept Limited, invented by Simon Westbrook, received European patent protection covering A61K therapeutic compositions. The patent designates all EPC contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NEUROTROPHIN BINDING PROTEIN P75NTR FOR USE IN THE TREATEMENT OF OSTEOARTHRITIS

Publication EP3169347A1 Kind: A1 Apr 08, 2026

Applicants

Levicept Limited

Inventors

WESTBROOK, Simon

IPC Classifications

A61K 38/17 20060101AFI20260305BHEP A61K 45/06 20060101ALI20260305BHEP A61K 47/60 20170101ALI20260305BHEP A61K 47/64 20170101ALI20260305BHEP A61P 19/02 20060101ALI20260305BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3169347A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent issuance IP rights grant
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!